Canakinumab, an IL-1β antibody, has been shown to prevent the recurrence of ischemic events in patients with prior acute myocardial infarction in a large phase III clinical trial, involving 10.061 participants worldwide [72], Ridker et al., 2017. This evidence concerns the gene IL1B and acute myocardial infarction.